This Plain Language Summary of Publication article (PLSP) from Future Cardiology presents results from THAOS, a real-world study examining tafamidis treatment in people with transthyretin amyloid cardiomyopathy (ATTR-CM) who had both heart and nerve symptoms. Researchers compared survival rates, hospitalization frequency and duration, and side effects between patients who received tafamidis and those who did not, providing insights into the medication’s real-world effectiveness and safety profile.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Survival in a Contemporary, Real-World Cohort of Patients with Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: An Analysis from THAOS’ and was published in Cardiology and Therapy.

Visit Springer Nature using the link to read the original article.